Loading…
Pharmaceuticals and Biotechnology · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.7% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 3.18% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0.15% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 2.86% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.7% of any dividend from LAURUSLABS should be given to charity. Calculate your amount →
Strong gains over 3–6 months, positive 1-month returns, 50-day above 200-day, and price just a few percent off the 52-week high indicate a well-established uptrend in recent performance. Sector sentiment is not specified, so the backdrop appears stock-specific.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.